Protection against *Clostridium difficile* infection in a hamster model by oral vaccination using flagellin FliC-loaded pectin beads.

1

2 JF. Bruxelles^a, N. Tsapis^b, S. Hoys^a, A. Collignon^a, C. Janoir^a, E. Fattal^b, S. Péchiné^{a*}

3 ^a EA4043 Unités Bactéries Pathogènes et Santé (UBaPS), Univ. Paris-Sud, Université Paris-Saclay,
4 Châtenay-Malabry, France

5 ^b Institut Galien Paris-Sud, CNRS, Univ. Paris-Sud, Université Paris-Saclay, Châtenay-Malabry,
6 France

7 * **Corresponding author:** Séverine Péchiné

8 E-mail address: severine.pechine@u-psud.fr

9 Postal Address: Université Paris-Sud, UFR de Pharmacie, 5 rue J.B. Clément, 92296 Chatenay-
10 Malabry cedex

11 **Abstract**

12 *Clostridium difficile* flagellin FliC is a highly immunogenic pathogen-associated molecular pattern
13 playing a key role in *C. difficile* pathogenesis and gut colonization. Here, we designed an oral vaccine
14 against *C. difficile* with FliC encapsulated into pectin beads for colonic release. Bead stability and
15 FliC retention was confirmed in vitro using simulated intestinal media (SIM), while bead degradation
16 and FliC release was observed upon incubation in simulated colonic media (SCM). The importance
17 of FliC encapsulation into pectin beads for protection against *C. difficile* was assessed in a
18 vaccination assay using a lethal hamster model of *C. difficile* infection. Three groups of hamsters
19 orally received either FliC-loaded beads or unloaded beads in gastro-resistant capsule to limit gastric
20 degradation or free FliC. Two other groups were immunized with free FliC, one intra-rectally and the

other intra-peritoneally. Hamsters were then challenged with a lethal dose of *C. difficile* VPI 10463. Fifty percent of hamsters orally immunized with FliC-loaded beads survived whereas all hamsters orally immunized with free FliC died within 7 days post challenge. No significant protection was observed in the other groups. Only intra-peritoneally immunized hamsters presented anti-FliC IgG antibodies in sera after immunizations. These results suggest that an oral immunization with FliC-loaded beads probably induced a mucosal immune response, therefore providing a protective effect. This study confirms the importance of FliC encapsulation into pectin beads for a protective oral vaccine against *C. difficile*.

Keywords: *Clostridium difficile*; oral vaccination; flagellin; pectin beads; colonic delivery

1 Introduction

Clostridium difficile (*Clostridioides*) *difficile* [1] is a Gram-positive, anaerobic spore-forming bacterium and is the leading cause of antibiotic-associated diarrhea. Gut microbiota dysbiosis enables *C. difficile* colonization of the intestinal tract. After contamination, *C. difficile* spores germinate, vegetative forms multiply, and toxins are released, disrupting epithelium integrity and inducing an inflammatory response in the colon [2]. *C. difficile* is a non-invasive pathogen, thus, promoting local intestinal immunity could trigger early protection against *C. difficile* infection (CDI) [3]. **Even though the intra-rectal route has shown promising results previously by inducing a protective immune response directed to *C. difficile*** [4-6], developing the oral route of immunization represents a rational choice to induce a gut mucosal immune response with a better patient acceptance and comfort. To overcome the gastrointestinal barrier, antigen encapsulation is recommended to maintain its integrity and its immunogenicity. Biocompatible and biodegradable polymers are interesting materials for encapsulation. For instance, pectin, a non-toxic polysaccharide,

44 has previously shown promising capacity for protein encapsulation and colonic delivery [7, 8].
45 Indeed, pectin is not degraded by gastric or intestinal enzymes but is almost totally degraded by
46 pectinolytic enzymes produced by the microbiota present in the colon [7, 9].

47 Current strategies for vaccine development against *C. difficile* target either toxins or colonization
48 factors. Systemic vaccines targeting toxins are currently being tested in clinical trials
49 (NCT01887912; NCT03090191; NCT02316470) and have shown efficacy in protecting against **CDI**
50 **in animal models** [10, 11]. However, targeting colonization factors could prevent *C. difficile*
51 colonization, **growth** and symptomatic infection therefore limiting dissemination of the bacteria in
52 the environment. Several vaccine candidates targeting colonization factors showed promising results
53 [4, 8, 12]. For instance, flagellin which is highly immunogenic, harbors a unique pathogen-associated
54 molecular pattern implicated in toll-like receptor-5 (TLR-5) recognition. However, the central
55 domain of the flagellin is highly variable among different species [13, 14]. Regarding *C. difficile*
56 flagellin, FliC is a 39 kDa structural protein of the flagellum. The central domain, the N- and C-
57 terminal domains of FliC are well conserved among the different strains of *C. difficile*. FliC
58 antibodies have been detected in patient sera [15] and non-CDI patients presented significantly more
59 anti-FliC serum antibodies than CDI patients [16]. Interestingly, the immunological properties of
60 FliC enable it to act as adjuvant [17] and as antigen, so, FliC represents a promising vaccine
61 candidate [12, 18]. Ghose *et al.* intraperitoneally immunized hamsters and mice with FliC and
62 described the induction of a systemic IgG response protective against **CDI** [12].

63 **Developing a mucosal vaccine targeting *C. difficile* gut colonization could enable early**
64 **protection against CDI. Oral vaccines can be expected to have much greater acceptability than**
65 **injectable vaccines. Oral vaccine administration could also lead to simplified manufacturing**
66 **vaccine, thereby increasing the potential for local vaccine production.** Here we describe the
67 development and the efficacy of a mucosal vaccine strategy with FliC against *C. difficile* virulence in

hamster. To this end, here we first assess the suitability of pectin beads to deliver FliC into the colon and we evaluate FliC-loaded pectin beads in gastro-resistant capsules as an oral vaccine candidate against *C. difficile* in a lethal hamster model of **CDI**.

2 Material and methods

2.1 Preparation of pectin beads

Recombinant FliC was obtained and purified as previously described [13] with exception that the purified protein was dialyzed against TRIS buffer (25 mM, pH 7.5). Pectin beads were prepared as previously detailed [8], pectin solution was obtained with UnipectineTM OG175C (Cargill) dissolved in TRIS buffer (25 mM, pH 7.5) at the concentration of 6% (w/V). Unloaded beads were prepared with the pectin solution only and FliC-loaded beads with pectin solution and recombinant FliC. The pectin solution containing FliC or not was then dropped into a cross-linking solution of Zn acetate (12%, w/V). Beads, formed instantaneously by contact with zinc ions, were left in the cross-linking solution for 30 minutes at room temperature under magnetic stirring. Beads were washed three times with distilled water and then dried 3 hours at 37°C. To determine encapsulation **efficiency (EE)**, FliC-loaded beads were disintegrated in TRIS buffer (25 mM, pH 7.5) added with EDTA (50 mM). Then, proteins were dosed using Bradford dye-binding method. **EE(%) was determined by the following formula : (actual amount of FliC encapsulated / theoretical amount of FliC encapsulated) *100.**

2.2 Analysis of protein release from beads in simulated digestive media

Analysis of FliC release was carried out in two different simulated digestive media as previously described [8]: 5 h in Simulated Intestinal Medium (SIM, HEPES/NaCl buffer, pH 6.8) containing pancreatin (1% w/V) followed by 5 h in Simulated Colonic Medium (SCM, HEPES/NaCl buffer, pH 6) containing ≥ 760 U/mL of pectinase from *Aspergillus aculeatus* (Sigma). Presence of FliC and

pectinase in the same medium makes difficult to dose proteins by Bradford dye-binding method. Therefore, loaded beads were prepared using rhodamine-labelled FliC. Labeling and release protocol were performed as previously described [8] and the amount of FliC released was determined by spectrofluorometry in duplicate.

2.3 Gastro-resistant coating of capsules containing beads for oral immunization

To protect beads from the harsh gastric acid environment, loaded and unloaded beads were placed into gelatin capsules (size 9, Harvard Apparatus) coated with a hydroxypropyl methylcellulose phthalate (HPMCP 50) film. Coating was performed by dipping capsules into a 10% (w/V) solution of HPMCP 50 in acetone/ethanol (1:1 v:v) and drying them at room temperature [8]. This process was repeated six times. The efficacy of the gastro-resistant coating was checked by a disintegration test according to European pharmacopoeia (capsules undamaged after 2 h in HCl 0.1 M) [8].

2.4 Animals

The vaccination study was carried out in a model of infection using *Mesocricetus auratus* female hamsters (weight, 80–100 g, Janvier Laboratories). Protocols involving animals and their care were conducted in conformity with the institutional guidelines that are in compliance with national and international laws and policies. The protocol was approved by the Committee on the Ethics of Animal Experiments University of Paris-Sud and the French Minister of Research (APAFIS#4577-2016020913152994 v4). All efforts were made to minimize animal suffering.

2.5 Vaccination protocol

Five groups of 6 animals were used. Each vaccinated animals received a total of 300 µg of FliC in three administrations of 100 µg of FliC every fifteen days (**at day 0, day 15 and day 30**). One group was immunized with FliC-loaded pectin beads given orally and a group orally received unloaded

beads. Three other groups were immunized with recombinant free FliC by oral, intra-rectal or intra-peritoneal route. **Fifteen days after the last immunization (at day 45) and before *C. difficile* challenge**, hamsters were orally given clindamycin at a single dose of 50 mg/kg and gentamicin twice a day during 5 days **(from day 45 to day 49)** at a dose of 2.5 mg/kg to disrupt the intestinal microbiota. Then **at day 50**, hamsters were orally challenged with 7.5×10^4 spores of *C. difficile* strain VPI 10463 (Fig. 1). Two days after challenge, ***C. difficile* colonization** was checked by detection of *C. difficile* vegetative cells in the feces **by plating adequate dilutions on Columbia agar containing 5% of horse blood, 25% (w/v) of D-cycloserine, and 0.8% (w/v) of cefoxitin and taurocholate.**

2.6 Evaluation of specific antibody level in sera after immunization

To evaluate the antibody response in sera, blood samples were withdrawn before the first immunization and 15 days after the last immunization, before *C. difficile* challenge. Indirect ELISA was used to detect antibodies in the sera as previously described [6]. Briefly, wells of 96-well microtitre plates (MaxiSorp, Nunc) were coated with 100 μ L of a 5 μ g/mL solution of recombinant purified FliC. Sera were tested in duplicate at dilution 1:500 in 100 μ L final volume. After five washings with phosphate buffer (PBS) and Tween-20 (0.1%), an aliquot of 100 μ L per well of a rabbit anti-hamster IgG conjugated with biotin (1:8,000 dilution; Biovalley) was added and plates were incubated for 30 min at 37°C. Then, after five washings, 100 μ L per well of streptavidin–HRP (1:10,000 dilution; ThermoScientific) were added and plates were incubated for 30 min at 37°C. Assays with antigen in the absence of sera served as negative controls. Immunoglobulin levels are expressed as OD units at 450 nm.

2.7 Statistical analysis

Animal surviving rate was analyzed using Kaplan–Meier estimates. Survival rates between groups were compared using log rank test, p-values < 0.05 were considered as statistically significant. Mann-Whitney U-test was performed to analyzed specific anti-FliC antibody levels in sera after immunizations, p-values < 0.05 were considered as statistically significant.

3 Results

3.1 Flagellin encapsulation in pectin beads and *in vitro* release

In order to perform oral vaccination, we encapsulated the recombinant *C. difficile* flagellin FliC into pectin beads. About 40 to 45 beads were obtained per milliliter of pectin solution. After drying, beads had an ellipsoid shape with a 1.2-1.5 mm diameter and weighed between 1.5 and 2 mg (Fig. 2). The total amount of encapsulated FliC was dosed after total disintegration of beads. FliC-loaded bead contained a total amount of 3 ± 1 µg of FliC by bead, this corresponds to an encapsulation **efficiency** of about $30 \pm 10\%$ (n=5). *In vitro* characterization confirms beads stability in SIM and protein release in SCM containing pectinase. Less than 10% of FliC was released after 5 h of incubation in SIM and dried beads swelled keeping their shape. After being placed in SCM, beads started to disintegrate leading to the release of FliC. Between 2 and 3 h were sufficient to release more than 80% of entrapped FliC (Fig. 3). This *in vitro* characterization of FliC-loaded beads confirms the interest of using this encapsulation strategy for colonic delivery of an antigen after oral administration.

3.2 Vaccination with flagellin against **CDI** in the hamster model

C. difficile flagellin FliC is a promising vaccine candidate. To evaluate the efficacy of mucosal vaccination with FliC against *C. difficile* virulence, we immunized hamsters with the same amount of FliC via different mucosal routes and compare them with the intra-peritoneal parenteral route. We showed here that encapsulation of FliC into pectin beads for oral administration significantly

protected hamsters against *C. difficile* lethal challenge (Fig. 4). Indeed, at day 17 after challenge, 50% of hamsters survived in the group orally vaccinated with FliC-loaded beads, whereas no survival was observed after oral vaccination with free FliC (p-value=0.041). Only 17% of hamsters (n=1) survived in the unloaded bead group. The same percentage of surviving animals was observed for the intra-rectally vaccinated group. After immunization by intra-peritoneal route, 33% of hamsters survived. Interestingly, analysis of *C. difficile* fecal shedding showed that, whereas all 30 animals were infected by *C. difficile* two days post-challenge, all surviving animals in the different groups were no more colonized at the end of the assay at 17 days post challenge. These results showed that oral vaccination with FliC-loaded pectin beads led to the best protection against *C. difficile* virulence in the hamster model.

3.3 Antibody response induced after vaccination

To correlate the observed protection with the systemic immune response induced by vaccination, we evaluated the anti-FliC response in sera. We observed an increased level of FliC-specific IgG antibodies in sera after intra-peritoneal immunizations of hamsters. In contrast, in the other groups, no significant increase of anti-FliC-specific serum IgG level was observed (Fig. 5).

4 Discussion

As *C. difficile* is a non-invasive enteropathogen, the induction of a mucosal immune response close to the site of infection appears to be a relevant choice for inducing protection. Vaccine development against non-invasive gastrointestinal infections such as enterotoxigenic *Vibrio cholerae* or *Escherichia coli* showed that the protection is conferred mainly by specific secretory IgA (sIgA) and by the induction of a memory immune response [19]. A mucosal vaccine strategy, which aims to prevent alteration of the intestinal epithelium by targeting the early stages of the *C. difficile* infectious process, could benefit from further attention.

Furthermore, one of the vaccine strategies against *C. difficile* is to target surface proteins involved in intestinal colonization. The flagellin FliC appears a promising vaccine candidate, since Ghose *et al.* reported that intra-peritoneal immunization with FliC and alum led to 43 to 64% of protection in a hamster model and 40 to 100% protection in a mouse model in a dose-dependent manner [12]. In our assay, intra-peritoneal immunization of hamsters with FliC led to 33% of survival against *C. difficile*. Compared to Ghose *et al* results [12], this difference of protection is probably due to the adjuvant used for immunization. Indeed, as already demonstrated, *C. difficile* flagellin FliC has adjuvant properties, avoiding alum use as adjuvant [12, 17]. Consequently in our study, immunizations were performed without additional adjuvant. In addition, *C. difficile* strain used for challenge was not the same, with probably a difference of virulence between the VPI 10463 strain used here and the 630 Δ *erm* strain used in Ghose *et al* study, as described elsewhere [20]. Of note here, we demonstrated that the high immunogenicity of FliC enables to induce a strong systemic IgG antibody response after intra-peritoneal immunization without supplementary adjuvant.

Interestingly, here we obtained a better protection with an oral vaccine consisting of FliC encapsulated into pectin beads to target colonic release than after intra-peritoneal immunization with purified FliC alone. We showed that this strategy can significantly protect 50% of hamsters from CDI (3 out of 6). However, these results should be confirmed in a larger study. This significant but partial protection confirms the multifactorial aspect of colonization, suggesting that a combination of several proteins will be necessary to trigger an efficient immune response against *C. difficile* colonization factors, and consequently to prevent the colonization process. In addition, according to animal variability to *C. difficile* infection, especially regarding immune response and microbiota, a combined vaccine could be necessary.

Ghose *et al.* demonstrated that the protection induced by FliC immunization by intra-peritoneal route was anti-FliC IgG-mediated. In our study, the immune response induced after oral immunization with

204 FliC-loaded pectin beads is able to partially protect animal from death. However, no specific IgG
205 antibody response was detected in sera. This was previously observed in another assay of oral
206 vaccination of hamsters with the Cwp84 protease encapsulated in pectin beads. Although vaccinated
207 hamsters were partially protected (40%) against CDI, they did not develop a systemic anti-Cwp84-
208 IgG antibody response [8]. This suggests that after vaccination by mucosal route, beside a systemic
209 immune response, a local immune response with sIgA production could be the key factor of
210 protection. It has been previously shown in a mouse model that parenteral immunization with
211 flagellin can activate mucosal dendritic cells and induce an isotype switch to IgA [18]. Unfortunately
212 secondary antibodies are not commercially available to detect specific IgA in hamsters.

213 Here, we used the hamster model of CDI, which is highly sensitive to this infection and reflects more
214 severe infection in human than mild infection. Our results indicate that in this model, protection
215 could probably be related to neutralizing sIgA but other factors may play an important role in the
216 host immune response against **CDI**. In particular, our immunization strategy might have generated a
217 wider cell-based immunity that could have induced partial protection. Regarding *Streptococcus*
218 *pneumoniae*, it has been demonstrated that multiple immune cell types are required for the induction
219 of a protective immunity in a murine model which lacks mature B cells and fails to produce antibody
220 [21]. Further studies are needed to specify the immune effectors induced by immunization.

221 In this study, the least protection of hamsters observed by intra-rectal administration of FliC
222 compared to the oral administration of FliC-loaded beads and the absence of protection for the free
223 FliC orally treated group, is presumably due to the degradation of the free antigen by gut enzymes
224 before it reaches the colon. This further confirms the importance of the administration route and the
225 use of pectin beads as a delivery system for FliC.

226 To conclude, we showed that oral vaccination with *C. difficile* FliC-loaded pectin beads is partially
227 protective against a virulent strain of *C. difficile* in a hamster model. **In order to assess in further**
228 **depth the mechanisms of protection, further studies in mouse model could inform on the**
229 **protection against *C. difficile* colonization and a better understanding of the immune response**
230 **elicited with this vaccine.** This study confirms the importance of the adequacy between the
231 administration route, the delivery system and the vaccine candidate in the design of a mucosal
232 protective immunization strategy targeting *C. difficile*.

233 **Acknowledgments**

234 This work was supported by the technical assistance of Valerie Dupont-Domergue and staff from the
235 animal care facility of IPSIT.

236 **Funding**

237 Jean-François Bruxelles's PhD was funded by the French Ministry of Research and Higher Education

238 **Conflict of interest**

239 No conflicts of interest to declare.

240

241 **Figures**

243 **Figure 1.** Vaccination protocol.

244 Animals received a total of 300 µg of FliC in three administrations of 100 µg of FliC on days 0, 15
245 and 30. Before challenge, hamsters received clindamycin and gentamicin to disrupt the intestinal
246 microbiota. Then, hamsters were orally challenged by 7,5x10⁴ spores of *C. difficile* strain VPI 10463.
247 Two days after challenge **CDI** was checked by detection of *C. difficile* in the feces. Blood samples
248 were withdrawn before the first immunization and 15 days after the last immunization to evaluate the
249 antibody response in sera.

250

251

252

253 **Figure 2.** Dried pectin beads (scale bar represents 1 cm).

254

255 Figure 3. In vitro FliC release from pectin beads in Simulated Intestinal Medium (SIM) for 5h and
 256 Simulated Colonic Medium (SCM) for other 5h (n=2).

257

258 Figure 4. Kaplan-Meier survival estimates after immunizations. One group was immunized with
 259 FliC-loaded beads given orally (FliC-loaded beads), one group orally received unloaded pectin beads
 260 (Unloaded beads) and three other groups were immunized with recombinant free FliC by oral (FliC
 261 oral), intra-rectal (FliC intra-rectal) or intra-peritoneal route (FliC intra-peritoneal). After challenge
 262 with spores of *C. difficile* VPI 10463 strain, animals were monitored for 17 days. * p-value < 0.05

Figure 5. Detection of specific IgG in animal sera by ELISA. Mean of anti-FliC-specific IgG in serum of immunized hamsters (diluted 1:500) before (D0) and after vaccination (D45). Sera of hamsters were analysed by ELISA. *: statistically significant difference p-value < 0.05 (Mann-Whitney U-test).

References

- [1] Lawson PA, Citron DM, Tyrrell KL, Finegold SM. Reclassification of *Clostridium difficile* as *Clostridioides difficile* (Hall and O'Toole 1935) Prévot 1938. *Anaerobe* 2016 Aug 2016;40:95-9.
- [2] Koenigsknecht MJ, Theriot CM, Bergin IL, Schumacher CA, Schloss PD, Young VB. Dynamics and Establishment of *Clostridium difficile* Infection in the Murine Gastrointestinal Tract. *Infection and Immunity* 2015 03/2015;83:934-41.

281 [3] Péchiné S, Collignon A. Immune responses induced by *Clostridium difficile*. Anaerobe 2016
282 Oct 2016;41:68-78.

283 [4] Bruxelles J-F, Mizrahi A, Hoys S, Collignon A, Janoir C, Péchiné S. Immunogenic properties
284 of the surface layer precursor of *Clostridium difficile* and vaccination assays in animal models.
285 Anaerobe 2016 Feb 2016;37:78-84.

286 [5] Mizrahi A, Collignon A, Péchiné S. Passive and active immunization strategies against
287 *Clostridium difficile* infections: state of the art. Anaerobe 2014 Dec 2014;30:210-9.

288 [6] Péchiné S, Denève C, Le Monnier A, Hoys S, Janoir C, Collignon A. Immunization of
289 hamsters against *Clostridium difficile* infection using the Cwp84 protease as an antigen. FEMS
290 Immunology & Medical Microbiology 2011 10/2011;63:73-81.

291 [7] Bourgeois S, Laham A, Besnard M, Andreumont A, Fattal E. In vitro and in vivo evaluation of
292 pectin beads for the colon delivery of beta-lactamases. Journal of Drug Targeting 2005 Jun
293 2005;13:277-84.

294 [8] Sandolo C, Péchiné S, Le Monnier A, Hoys S, Janoir C, Coviello T, et al. Encapsulation of
295 Cwp84 into pectin beads for oral vaccination against *Clostridium difficile*. 2011 Nov 2011;79:566-
296 73.

297 [9] Ndeh D, Rogowski A, Cartmell A, Luis AS, Basle A, Gray J, et al. Complex pectin
298 metabolism by gut bacteria reveals novel catalytic functions. Nature 2017 Apr 6;544(7648):65-70.

299 [10] Anosova NG, Brown AM, Li L, Liu N, Cole LE, Zhang J, et al. Systemic antibody responses
300 induced by a two-component *Clostridium difficile* toxoid vaccine protect against C. difficile-
301 associated disease in hamsters. Journal of Medical Microbiology 2013 Sep 2013;62:1394-404.

302 [11] Kocielek LK, Gerding DN. Breakthroughs in the treatment and prevention of *Clostridium*
303 *difficile* infection. Nature Reviews Gastroenterology & Hepatology 2016 Mar 2016;13:150-60.

304 [12] Ghose C, Eugenis I, Sun X, Edwards AN, McBride SM, Pride DT, et al. Immunogenicity and
305 protective efficacy of recombinant *Clostridium difficile* flagellar protein FliC. Emerging Microbes &
306 Infections 2016 Feb 03, 2016;5:e8.

307 [13] Batah J, Denève-Larrazet C, Jolivot P-A, Kuehne S, Collignon A, Marvaud J-C, et al.
308 *Clostridium difficile* flagella predominantly activate TLR5-linked NF-κB pathway in epithelial cells.
309 Anaerobe 2016 Apr 2016;38:116-24.

310 [14] Rumbo M, Nempont C, Kraehenbuhl J-P, Sirard J-C. Mucosal interplay among commensal
311 and pathogenic bacteria: Lessons from flagellin and Toll-like receptor 5. FEBS Letters 2006 2006-
312 05-22;580:2976-84.

313 [15] Wright A, Drudy D, Kyne L, Brown K, Fairweather NF. Immunoreactive cell wall proteins of
314 *Clostridium difficile* identified by human sera. Journal of medical microbiology 2008 Jun
315 2008;57:750-6.

316 [16] Péchiné S, Gleizes A, Janoir C, Gorges-Kergot R, Barc M-C, Delmée M, et al.
317 Immunological properties of surface proteins of *Clostridium difficile*. Journal of medical
318 microbiology 2005 Feb 2005;54:193-6.

319 [17] Bruxelles J-F, Mizrahi A, Hoys S, Collignon A, Janoir C, Péchiné S. *Clostridium difficile*
320 flagellin FliC: Evaluation as adjuvant and use in a mucosal vaccine against *Clostridium difficile*. PloS
321 One 2017 2017;12:e0187212.

- 322 [18] Flores-Langarica A, Marshall JL, Hitchcock J, Cook C, Jobanputra J, Bobat S, et al. Systemic
323 flagellin immunization stimulates mucosal CD103+ dendritic cells and drives Foxp3+ regulatory T
324 cell and IgA responses in the mesenteric lymph node. *Journal of Immunology* (Baltimore, Md: 1950)
325 2012 Dec 15, 2012;189:5745-54.
- 326 [19] Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. *Nature Medicine* 2005 Apr
327 2005;11:S45-53.
- 328 [20] Theriot CM, Koumpouras CC, Carlson PE, Bergin II, Aronoff DM, Young VB.
329 Cefoperazone-treated mice as an experimental platform to assess differential virulence of *Clostridium*
330 *difficile* strains. *Gut Microbes* 2011 2011 Nov-Dec;2:326-34.
- 331 [21] McCool TL, Weiser JN. Limited role of antibody in clearance of *Streptococcus pneumoniae*
332 in a murine model of colonization. *Infect Immun* 2004 Oct;72(10):5807-13.

333

334